Screener
Bicara Therapeutics BCAX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total other income | 4,083 | 5,014 |
| Net loss before income taxes | (56,159) | (36,774) |
| Income tax expense | (52) | (72) |
| Net loss | $(56,211) | $(36,846) |
| Net Loss per share, basic and diluted | $(0.93) | $(0.68) |
| Weighted-average number common shares outstanding, basic and diluted | 60,717,041 | 54,456,515 |
| Other comprehensive loss: | ||
| Unrealized loss on marketable securities, net of tax | (486) | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's net income?
- Bicara Therapeutics (BCAX) reported net income of -$56.21M in Q1 2026.
- How has Bicara Therapeutics's net income changed year-over-year?
- Bicara Therapeutics's net income decreased by 52.6% year-over-year, from -$36.85M to -$56.21M.
- What is the long-term trend for Bicara Therapeutics's net income?
- Over 2 years (2023 to 2025), Bicara Therapeutics's net income has grown at a 62.9% compound annual growth rate (CAGR), from -$51.99M to -$137.95M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Bicara Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude